Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA3 | P07451 | 1/20 | 0.40 |
| ▸ | CA6 | P23280 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.38 |
| ▸ | IDO1 | P14902 | 2/20 | 0.37 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.36 |
| ▸ | MMP3 | P08254 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | NOS3 | P29474 | 2/20 | 0.36 |
| ▸ | NOS1 | P29475 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL391676 | 1.00 | LOXL2 (0.41) | LOXL2CA2CA12CA3CA6 | |
| SCHEMBL14448531 | 0.84 | LOXL2 (0.43) | LOXL2CA2CA12CA3CA6 | |
| SCHEMBL8514968 | 0.84 | LOXL2 (0.43) | LOXL2CA2CA12CA3CA6 | |
| SCHEMBL5900978 | 0.84 | LOXL2 (0.43) | LOXL2CA2CA12CA3CA6 | |
| SCHEMBL25602618 | 0.81 | CA12 (0.34) | CA2CA12CA9CA14CA1 | |
| SCHEMBL21507539 | 0.79 | GRM4 (0.47) | IDO1ENPP2GSK3B | |
| SCHEMBL12488284 | 0.79 | GRM4 (0.47) | IDO1ENPP2GSK3B | |
| SCHEMBL13891122 | 0.78 | CA12 (0.41) | LOXL2CA2CA12CA3CA6 | |
| SCHEMBL24215016 | 0.77 | CA12 (0.36) | LOXL2CA2CA12CA3CA6 | |
| SCHEMBL27714563 | 0.77 | SLC2A1 (0.58) | LOXL2CA2CYP19A1CYP2A6ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12252495-B2 | Protein kinase B inhibitors | ASTRAZENECA AB (SE) | 2025-03-18 | — | — | US | disclosed |
| US-20240109902-A1 | PROTEIN KINASE B INHIBITORS | ASTRAZENECA AB (SE) | 2024-04-04 | — | — | US | disclosed |
| US-11760760-B2 | Protein kinase B inhibitors | ASTRAZENECA AB (SE) | 2023-09-19 | — | — | US | disclosed |
| US-11760760-B2 | Protein kinase B inhibitors | ASTRAZENECA AB (SE) | 2023-09-19 | — | — | US | disclosed |
| US-11760760-B2 | Protein kinase B inhibitors | ASTRAZENECA AB (SE) | 2023-09-19 | — | — | US | disclosed |
| US-20220220116-A1 | PROTEIN KINASE B INHIBITORS | ASTRAZENECA AB (SE) | 2022-07-14 | — | — | US | disclosed |
| US-20220220116-A1 | PROTEIN KINASE B INHIBITORS | ASTRAZENECA AB (SE) | 2022-07-14 | — | — | US | disclosed |
| US-11236095-B2 | Protein kinase B inhibitors | ASTRAZENECA AB (SE) | 2022-02-01 | — | — | US | disclosed |
| US-11236095-B2 | Protein kinase B inhibitors | ASTRAZENECA AB (SE) | 2022-02-01 | — | — | US | disclosed |
| US-20200239483-A1 | PROTEIN KINASE B INHIBITORS | ASTRAZENECA AB (SE) | 2020-07-30 | — | — | US | disclosed |
| US-20120190679-A1 | Novel Protein Kinase B Inhibitors - 060 | ASTRAZENECA AB (SE) | 2012-07-26 | — | — | US | disclosed |
| US-20120190679-A1 | Novel Protein Kinase B Inhibitors - 060 | ASTRAZENECA AB (SE) | 2012-07-26 | — | — | US | disclosed |
| US-8101623-B2 | Substituted pyrrolo[2,3-d]pyrimidine as a protein kinase B inhibitor | ASTRAZENECA AB (SE) | 2012-01-24 | — | — | US | disclosed |
| US-8101623-B2 | Substituted pyrrolo[2,3-d]pyrimidine as a protein kinase B inhibitor | ASTRAZENECA AB (SE) | 2012-01-24 | — | — | US | disclosed |
| CN-101861321-A | Pyrrolo [2, 3 -D] pyrimidin derivatives as protein kinase B inhibitors | ASTRAZENECA AB | 2010-10-13 | — | — | CN | disclosed |
| EP-2201012-A1 | PYRROLO [2, 3 -D] PYRIMIDIN DERIVATIVES AS PROTEIN KINASE B INHIBITORS | AstraZeneca AB (SE) | 2010-06-30 | — | — | EP | disclosed |
| US-20090163524-A1 | Novel Protein Kinase B Inhibitors - 060 | ASTRAZENECA AB (SE) | 2009-06-25 | — | — | US | disclosed |
| US-20090163524-A1 | Novel Protein Kinase B Inhibitors - 060 | ASTRAZENECA AB (SE) | 2009-06-25 | — | — | US | disclosed |
| WO-2009047563-A1 | PYRROLO [2, 3 -D] PYRIMIDIN DERIVATIVES AS PROTEIN KINASE B INHIBITORS | ASTRAZENECA AB (SE) | 2009-04-16 | — | — | WO | disclosed |
| WO-2009047563-A1 | PYRROLO [2, 3 -D] PYRIMIDIN DERIVATIVES AS PROTEIN KINASE B INHIBITORS | ASTRAZENECA AB (SE) | 2009-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12252495-B2 | Protein kinase B inhibitors | PRKAR2B, PRKCB, AKT1 | LOXL2 3612/4885CA2 1925/4885CA12 4344/4885 |
| US-20220220116-A1 | PROTEIN KINASE B INHIBITORS | PRKAR2B, PRKCB, AKT1 | LOXL2 3612/4885CA2 1925/4885CA12 4344/4885 |
| US-20240109902-A1 | PROTEIN KINASE B INHIBITORS | PRKAR2B, PRKCB, AKT1 | LOXL2 3612/4885CA2 1925/4885CA12 4344/4885 |
| US-20090163524-A1 | Novel Protein Kinase B Inhibitors - 060 | PRKAR2B, PRKCB, MAP3K20 | LOXL2 3697/4885CA2 2920/4885CA12 4656/4885 |
| US-20200239483-A1 | PROTEIN KINASE B INHIBITORS | PRKAR2B, PRKCB, AKT1 | LOXL2 3612/4885CA2 1925/4885CA12 4344/4885 |
| US-20120190679-A1 | Novel Protein Kinase B Inhibitors - 060 | PRKAR2B, PRKCB, MAP3K20 | LOXL2 3697/4885CA2 2920/4885CA12 4656/4885 |
| US-11236095-B2 | Protein kinase B inhibitors | PRKAR2B, PRKCB, AKT1 | LOXL2 3612/4885CA2 1925/4885CA12 4344/4885 |
| US-11760760-B2 | Protein kinase B inhibitors | PRKAR2B, PRKCB, AKT1 | LOXL2 3612/4885CA2 1925/4885CA12 4344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.